Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;25(5):984–994. doi: 10.1093/neuonc/noac229

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

PMC Copyright notice

Figure 2. — Kaplan–Meier curves for PFS and OS separated by relative changes of the maximum tumor-to-brain ratio (TBR_max) (top row), metabolic tumor volume (MTV) (middle row), and the of occurrence of new hotspots (bottom row) on FET PET after two cycles of lomustine-based chemotherapy. Responders on FET PET defined by any decrease or an unchanged TBR_max and/or MTV at follow-up compared to baseline had a significantly longer PFS (both 6.5 vs. 2.6 months; P < .001) and OS (TBR_max, 13.7 vs. 9.1 months; P = .015; MTV, 12.8 vs. 8.8 months; P = .045) than non-responders (ie, patients with an increase of TBR_max and/or MTV at follow-up compared to baseline). Non-responders on FET PET defined by the occurrence of any new distant hotspot at follow-up compared to baseline had a significantly shorter PFS (2.1 vs. 4.0 months, P = .005) and OS (6.8 vs. 13.1 months, P < .001) than patients without any new distant hotspots at follow-up.